Nivolumab

SAN FRANCISCO — Transurethral resection of bladder tumor followed by systemic therapy induced stringently defined clinical complete response among more than 40% of patients with muscle-invasive bladder cancer, according to phase 2 study results.

Treatment with neoadjuvant nivolumab led to higher 5-year survival rates compared with historical data among patients with resectable non-small cell lung cancer, according to study results published in Clinical Cancer Research.

High BMI appeared associated with increased risk for any-grade immune-related adverse events among a cohort of patients with advanced cancer undergoing treatment with immune checkpoint inhibitors.

The addition of brentuximab vedotin and nivolumab to doxorubicin and dacarbazine appeared promising for adults with bulky stage II or stage III/stage IV classic Hodgkin lymphoma, according to study results.

Several novel treatment regimens for melanoma/skin cancer emerged during the past year.

NEW ORLEANS — The addition of brentuximab vedotin and nivolumab to doxorubicin and dacarbazine appeared active among patients with advanced-stage classical Hodgkin lymphoma, according to study results.

In this video, Maria E. Cabanillas, MD, an oncologic endocrinologist at The University of Texas MD Anderson Cancer Center, discussed important research on immunotherapy combinations presented at American Thyroid Association Annual Meeting.

Most patients with renal cell carcinoma ineligible for surgery and ablation achieved tumor reduction after treatment with nivolumab plus ipilimumab, according to study results.

Cabozantinib combined with nivolumab and ipilimumab was "reasonably well tolerated," though it did not display an efficacy advantage over monotherapy, Bhavana Konda, MD, MPH, said in an interview with Healio.

More than half of patients had an objective response to first-line nivolumab for locally advanced or metastatic cutaneous squamous cell carcinoma, phase 2 study results published in Cancer showed.